

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



XtalPi Holdings Limited

晶泰控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2228)

**VOLUNTARY ANNOUNCEMENT
STRATEGIC**

**DRUG DISCOVERY COLLABORATION BETWEEN XTALPI
SUBSIDIARY LCC TECHNOLOGIES AND STANFORD UNIVERSITY**

This announcement is made by XtalPi Holdings Limited (the “**Company**” or “**XtalPi**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that LCC Technologies Ltd. (“**LCC Technologies**”), a wholly-owned subsidiary of the Company, and The Board of Trustees of the Leland Stanford Junior University (“**Stanford University**”), have entered into a drug discovery collaboration agreement (the “**Collaboration**”). The Collaboration brings together Stanford University’s disease biology research and LCC Technologies’ automated and AI-driven small molecule discovery platform to accelerate and empower the development of new medicines.

Under the Collaboration, new biological insights arising from Stanford University’s disease biology research will be evaluated for potential development into small molecule therapies using LCC Technologies’ proprietary PACE™ discovery platform. PACE™ combines fragment-based discovery, AI-driven computational design, automated synthesis and iterative design-make-test-analyse (DMTA) cycles.

The Collaboration is disease-agnostic. Under the Collaboration, principal investigators at Stanford University will have the opportunity to propose projects based on their research to a joint steering committee established by Stanford University and LCC Technologies (the “**Steering Committee**”). The Steering Committee will evaluate proposals based on scientific merit, tractability, and potential therapeutic impact, and select the most promising opportunities for further development towards clinical evaluation and beyond.

The Board considers that the Collaboration reinforces the Group's position in AI – and automation-powered drug discovery and provides opportunities for the Group, through LCC Technologies, to participate in early-stage collaborative programmes that seek to advance promising biological insights towards potential small molecule therapies. The Board further considers that the Collaboration is in the interests of the Company and its shareholders as a whole.

About LCC Technologies

LCC Technologies is a platform technology partner specialising in small molecule drug discovery. Founded in 2014 and spun off from the University of Liverpool, the business has been a pioneer in the development and application of chiral chemical space. Its proprietary discovery platform, PACE™, helps teams overcome bottlenecks that typically slow the progression of promising biological targets into viable drug candidates. Following its acquisition in 2025, LCC Technologies became a wholly owned subsidiary of XtalPi.

About XtalPi

XtalPi was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

By Order of the Board
XtalPi Holdings Limited
Dr. Wen Shuhao

Chairman of the Board and Executive Director

Hong Kong, 17 September 2026

As at the date of this announcement, the Board comprises Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan as executive directors, and Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang as independent non-executive directors.